New drug trial targets Tough-to-Treat bone cancers
NCT ID NCT07193550
Summary
This study is testing an investigational drug called zanzalintinib for adults with advanced bone sarcomas that have spread or returned after standard treatments. The main goals are to see if the drug can control the cancer's growth and for how long, and to monitor its safety. It is enrolling about 70 people with specific types of bone cancer, including osteosarcoma and Ewing sarcoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE SARCOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.